Annie P.

Director, Talent Acquisition & Business Development Operations | Cell Therapy | CDMO at Cellipont Bioservices

Annie P. has a diverse work experience in the field of talent acquisition and business development operations. Annie currently holds the position of Director of Talent Acquisition and Business Development Operations at Cellipont Bioservices, a cell therapy CDMO. Prior to this role, they were a Manager of Talent Acquisition for Biologics at Catalent Pharma Solutions, where they focused on the cell and gene therapy division. Annie also served as a Talent Acquisition Lead and US Site Lead for Catalent in Kansas City and Philadelphia, where they supported clinical supply operations and regulatory support. Before joining Catalent, Annie worked at ICON plc as a Senior Talent Acquisition Specialist, supporting recruitment in the Latin America region for clinical research. Annie also has experience as a Senior Business Consultant in Life Sciences and IT, and as a Business Development Manager and Account Manager in Clinical Research and IT at Global Employment Solutions. Their expertise lies in recruitment strategies, stakeholder management, and customer service.

Annie P. attended DCCC from 2000 to 2003, where they studied Business. In terms of additional certifications, they obtained multiple certifications from LinkedIn. In 2018, they completed courses such as "Change Management Foundations," "Developing Business Acumen," "Managing Teams," "Fred Kofman on Making Commitments," "Leading Effectively," and "Managing for Results." In 2020, they gained certifications in "Coaching Skills for Leaders and Managers," "Finance for Non-Financial Managers," "Gaining Skills with LinkedIn Learning," "Giving and Receiving Feedback," "Having Difficult Conversations," "Igniting Emotional Engagement," "Leading Inclusive Teams," "Leading Your Team Through Change," and "Rewarding Employees." Furthermore, they obtained the certification for "Inclusive Leadership" in May 2020.

Links


Timeline

  • Director, Talent Acquisition & Business Development Operations | Cell Therapy | CDMO

    October, 2022 - present